Advances in the use of milk thistle (Silybum marianum)

Integrative Cancer Therapies

Volumn 6, Issue 2, 2007, Pages 104-109

  Post White, Janice ^a   Ladas, Elena J ^b   Kelly, Kara M ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Cancer; Efficacy; Liver disease; Mechanism; Milk thistle; Safety; Silymarin

Indexed keywords

ASPARAGINASE; CISPLATIN; DOXORUBICIN; PLACEBO; SILIBININ; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; SILIDIANIN; SILIPHOS; SILYBUM MARIANUM EXTRACT; SILYMARIN; UNCLASSIFIED DRUG; VINCRISTINE;

ADJUVANT THERAPY; ALLERGIC REACTION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BILIARY TRACT DISEASE; BREAST CANCER; CANCER; CANCER INHIBITION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; HYPERLIPIDEMIA; LIVER CIRRHOSIS; LIVER PROTECTION; LIVER TOXICITY; MUSHROOM POISONING; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; REVIEW; SILYBUM MARIANUM; SKIN CANCER; T LYMPHOCYTE; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MILK THISTLE; NEOPLASMS; PHYTOTHERAPY; PLANT PREPARATIONS; TREATMENT OUTCOME;

EID: 34249915550     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735407301632     Document Type: Review

References (60)

1. PDR® for Herbal Medicines. 3 rd ed. Montvale, NJ: Medical Economics ; 2004.
2. Lee DY, Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (milk thistle). J Nat Prod. 2003 ; 66: 1171-1174.
3. Flora K., Hahn M., Rosen H., et al. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998 ; 93: 139-143.
4. Foster S. Milk Thistle: Silybum marianum. Rev ed. Austin, Tex: American Botanical Council ; 1999.
5. Blumenthal M, Busse WR, eds. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Austin, Tex: American Botanical Council ; 1998.
6. Ladas EJ, Cheng B., Hughes D., et al. Milk thistle (Silybum marianum) is associated with reductions in liver function tests (LFTs) in children undergoing therapy for acute lymphoblastic leukemia (ALL). Abstract presented at: Society of Integrative Oncology ; November 11, 2006 ; Boston, Mass.
7. Schroder FH, Roobol MJ, Boeve ER, et al. A randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol. 2005 ; 48: 922-930.
8. Greenlee H., Abascal K., Yarnell E., Ladas E. Clinical application of Silybum marianum in oncology. Integr Cancer Ther. 2007 ; 6: 158-165.
9. Campos R., Garrido A., Guerra R., et al. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med. 1989 ; 55: 417-419.
10. Hruby K., Csomos G., Fuhrmann M., et al. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol. 1983 ; 2: 183-195.
11. Farghali H., Kameniková L., Hynie S., et al. Silymarin effects on intracellular calcium and cytotoxicity: a study in perfused rat hepatocytes after oxidative stress injury. Pharmacol Res. 2000 ; 41: 231-237.
12. Lettéron P., Labbe G., Degott C., et al. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice: evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochem Pharmacol. 1990 ; 39: 2027-2034.
13. Campos R., Garrido A., Guerra R., et al. Acetaminophen hepatotoxicity in rats is attenuated by silybin dihemisuccinate. Prog Clin Biol Res. 1988 ; 280: 375-378.
14. Shear NH, Malkiewicz IM, Klein D., et al. Acetaminophen-induced toxicity to human epidermoid cell line A431 and hepatoblastoma cell line Hep G2, in vitro, is diminished by silymarin. Skin Pharmacol. 1995 ; 8: 279-291.
15. Valenzuela A., Guerra R., Garrido A. Silybin dihemisuccinate protects rat erythrocytes against phenylhydrazine-induced lipid peroxidation and hemolysis. Planta Med. 1987 ; 53: 402-405.
16. Zuber R., Modrianský M., Dvorák Z., et al. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res. 2002 ; 16: 632-638.
17. Venkataramanan R., Ramachandran V., Komoroski BJ, et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos. 2000 ; 28: 1270-1273.
18. Zhao J., Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis. 1999 ; 20: 2101-2108.
19. Sonnenbichler J., Mattersberger J., Rosen H. Stimulation of RNA synthesis in rat liver and isolated hepatocytes by silybin, an antihepatotoxic agent from Silybum marianum L. Gaertn. Hoppe Seylers Z Physiol Chem. 1976 ; 357: 1171-1180.
20. Sonnenbichler J., Zetl I. Mechanism of action of silibinin, V: effect of silibinin on the synthesis of ribosomal RNA, mRNA and tRNA in rat liver in vivo. Hoppe Seylers Z Physiol Chem. 1984 ; 365: 555-566.
21. Sonnenbichler J., Zetl I. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Prog Clin Biol Res. 1986 ; 213: 319-331.
22. Sonnenbichler J., Goldberg M., Hane L., et al. Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malignant cell lines. Biochem Pharmacol. 1986 ; 35: 538-541.
23. Comelli MC, Mengs U., Prosdocimi M., Schneider C. Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther. 2007 ; 6: 120-129.
24. Bhatia N., Zhao J., Wolf DM, et al. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett. 1999 ; 147: 77-84.
25. Zi X., Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci U S A. 1999 ; 96: 7490-7495.
26. Scambia G., De Vincenzo R, Ranelletti FO, et al. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. Eur J Cancer. 1996 ; 32A: 877-882.
27. Tyagi AK, Singh RP, Agarwal C., et al. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res. 2002 ; 8: 3512-3519.
28. Dhanalakshmi S., Agarwal P., Glode LM, Agarwal R. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin-and carboplatin-induced growth inhibition and apoptotic death. Int J Cancer. 2003 ; 106: 699-705.
29. Ladas EJ, Cheng B., Hughes D., et al. Milk thistle is associated with reductions in liver function tests in children undergoing therapy for acute lymphoblastic leukemia. Abstract presented at: American Society of Hematology ; December 10, 2006 ; Orlando, Fla.
30. Duthie SJ, Johnson W., Dobson VL The effect of dietary flavonoids on DNA damage (strand breaks and oxidised pyrimdines) and growth in human cells. Mutat Res. 1997 ; 390: 141-151.
31. Deep G., Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther. 2007 ; ADD ISSUE AND PAGE NUMBERS
32. Kroll DJ, Shaw HS, Oberlies NH Milk thistle nomenclature: Why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther. 2007 ; ADD ISSUE AND PAGE NUMBERS
33. Vailati A., Aristia L., Sozzé E., et al. Randomized open study of the dose-effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis. Fitoterapia. 1993 ; 64: 219-228.
34. Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver: a double-blind controlled study. Scand J Gastroenterol. 1982 ; 17: 517-521.
35. Parés A., Planas R., Torres M., et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol. 1998 ; 28: 615-621.
36. Flisiak R., Prokopowicz D. Effect of misoprostol on the course of viral hepatitis B. Hepatogastroenterology. 1997 ; 44: 1419-1425.
37. Angulo P., Patel T., Jorgensen RA, et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000 ; 32: 897-900.
38. Ferenci P., Dragosics B., Dittrich H., et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989 ; 9: 105-113.
39. Lucena MI, Andrade RJ, de la Cruz JP, et al. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis: results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther. 2002 ; 40: 2-8.
40. Velussi M., Cernigoi AM, De Monte A, et al. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997 ; 26: 871-879.
41. Albrecht M., Frerick H., Kuhn U., et al. Therapy of toxic liver pathologies with Legalon®. Z Klin Med. 1992 ; 47: 87-92.
42. Tanamly MD, Tadros F., Labeeb S., et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis. 2004 ; 36: 752.
43. Strickland GT, Tanamly MD, Tadros F., et al. Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C. Dig Liver Dis. 2005 ; 37: 542-543.
44. Gordon A., Hobbs DA, Bowden DS, et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006 ; 21: 275-280.
45. Enjalbert F., Rapior S., Nouguier-Soulé J., et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol. 2002 ; 40: 715-757.
46. Tamayo C., Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum). Integr Cancer Ther. 2007 ; 6: 146-157
47. Rambaldi A., Jacobs BP, Iaquinto G., Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2005 ;(2). CD003620.
48. Invernizzi R., Bernuzzi S., Ciani D., et al. Silymarine during maintenance therapy of acute promyelocytic leukemia. Haematologica. 1993 ; 78: 340-341.
49. Grossmann M., Hoermann R., Weiss M., et al. Spontaneous regression of hepatocellular carcinoma. Am J Gastroenterol. 1995 ; 90: 1500-1503.
50. Schroder FH, Roobol MJ, Boeve ER, et al. A randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol. 2005 ; 48: 922-930.
51. Hernandez R., Nazar E. Effect of silymarin in intrahepatic cholestasis of pregnancy. Revista chilena de Obstetricia y Ginecologia. 1982 ; 47: 22-29.
52. Allain H., Schück S., Lebreton S., et al. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease. Dementia Geriatr Cogn Disord. 1999 ; 10: 181-185.
53. Flaig T., Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007 ; 25: 139-146.
54. Ladas EJ, Kelly KM Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer? J Altern Complement Med. 2003 ; 9: 411-416.
55. Rainone F. Milk thistle. Am Fam Physician. 2005 ; 72: 1285-1288.
56. Jacobs BP, Dennehy C., Ramirez G., Sapp J., Lawrence VA Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med. 2002 ; 113: 506-515.
57. Saller R., Meier R., Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001 ; 61: 2035-2063.
58. Verma S., Thuluvath PJ Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol. 2007 Jan 10; [Epub ahead of print].
59. Coulter ID Evidence summaries and synthesis: necessary but insufficient approach for determining clinical practice of integrated medicine? Integr Cancer Ther. 2006 ; 5 ; 282-286.
60. Glasgow RE, Lichtenstein E., Marcus AC Why don't we see more translation of health promotion research to practice? Rethinking the efficacy-to- effectiveness transition. Public Health Matters. 2003 ; 93: 1261-1267.